Table 2. Prevalence and Extent of Intraprostatic Inflammation^* in Incident LUTS^** Cases and Controls, Placebo Arm, PCPT.

	Controls		Cases		P-Trend
	No or very low LUTS	Low LUTS	Moderate LUTS	High LUTS
All men	41	47	42	44
At least one biopsy core with inflammation***	66	64	69	73	0.4
Mean of the percentage of biopsy cores with inflammation	31	32	35	32	1.0
Mean of the mean of percentage of tissue area with inflammation
Overall	2.2	3.7	3.8	2.5	0.5
In men with at least one biopsy core with inflammation	3.3	5.8	5.5	3.4	0.4
In men without prostate cancer	34	42	36	39
At least one biopsy core with inflammation	65	67	67	77	0.3
Mean of the percentage of biopsy cores with inflammation	27	34	35	35	0.7
Mean of the mean of percentage of tissue area with inflammation
Overall	1.6	4.0	3.9	2.7	0.4
In men with at least one biopsy core with inflammation	2.5	6.0	5.8	3.5	0.3
In men without diabetes	40	46	38	38
At least one biopsy core with inflammation	65	65	68	74	0.4
Mean of the percentage of biopsy cores with inflammation	32	32	35	32	0.9
Mean of the mean of percentage of tissue area with inflammation
Overall	2.2	3.8	3.8	2.4	0.6
In men with at least one biopsy core with inflammation	3.4	5.8	5.5	3.3	0.4

^*Assessed in 3 cores of 6-10 obtained largely from the peripheral zone from transrectal ultrasound guided biopsies.

^**Controls had IPSS < 8 at baseline and year 7. Cases had an IPSS < 15 at baseline and IPSS at year 7 of 8-14 (low), 15-19 (moderate), and ≥20 (high).Of the men with low LUTS, 25 (53%) of them had a baseline IPSS < 8.

^***After multivariable adjustment for age; race; diabetes history; daily intake (continuous) of energy, polyunsaturated fat, total fat, total protein, red meat; number of alcoholic beverages per day(continuous); aspirin use: controls 66%, low LUTS 63%, moderate LUTS 70%, and high LUTS72%; P-trend = 0.4.